| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5615737 | The Journal of Heart and Lung Transplantation | 2017 | 10 Pages |
Abstract
Survival of patients with PoPH remains poor despite targeted therapy and worse than patients with idiopathic PAH. The benefit of PAH therapies in PoPH on long-term morbidity and mortality outcomes needs further consideration and study.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Sasiharan MRCP, Arun MD, FRCP, Logan MRCP, J. Gerry FRCP, Robin MD, MRCP, Konstantinos MD, MSc, PhD, Charlie A FRCP, Andrew J. PhD, FRCP, Sean MD, PhD, J. Simon R. FRCP, Michael A. MD, PhD, Clive MD, MRCP, Luke S. DPhil, FRCP, Martin FRCP, David G. FRCP,